Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $4.3 billion.

  • Takeda Pharmaceutical's Cash & Equivalents rose 4130.13% to $4.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 billion, marking a year-over-year increase of 4130.13%. This contributed to the annual value of $2.5 billion for FY2025, which is 2035.73% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Cash & Equivalents of $4.3 billion as of Q4 2025, which was up 4130.13% from $4.6 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Cash & Equivalents registered a high of $9.1 billion during Q1 2021, and its lowest value of $2.5 billion during Q1 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $4.1 billion (2023), whereas its average is $5.1 billion.
  • Per our database at Business Quant, Takeda Pharmaceutical's Cash & Equivalents skyrocketed by 5587.73% in 2021 and then crashed by 4483.39% in 2023.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Cash & Equivalents stood at $8.5 billion in 2021, then decreased by 29.24% to $6.0 billion in 2022, then crashed by 39.99% to $3.6 billion in 2023, then dropped by 16.57% to $3.0 billion in 2024, then soared by 41.3% to $4.3 billion in 2025.
  • Its last three reported values are $4.3 billion in Q4 2025, $4.6 billion for Q3 2025, and $2.7 billion during Q2 2025.